Trial Profile
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy [Eine randomisierte; doppelblinde placebokontrollierte Studie der Phase 2/3 zur Beurteilung der Sicherheit und Wirksamkeit von Davunetide zur Behandlung von progressiver supranukleärer Blickparese]
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Davunetide (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Allon Therapeutics
- 01 Apr 2022 Results published in the Movement Disorders
- 16 Sep 2020 Results of post-hoc analysis assessing Correlations between amantadine usage, gait, and cognition in PSP, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders.
- 24 Apr 2017 Results of a post-hoc analysis from NCT01110720 and NCT01049399 studies, published in the Movement Disorders.